Global R&D Pipeline
My Favorite
Hot Targets:
Nectin-4
Back
Total number of drugs
93
Phase II and later clinical stages
6.5%
Involving companies
122
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SHR-A2102 | SHR-A2102 | Antibody drug conjugate (ADC) | Neoplasms Skin and Musculoskeletal Diseases Urogenital Diseases Digestive System Disorders Respiratory Diseases | TOP1 inhibitors nectin-4 inhibitors | Shanghai Hengrui Pharmaceutical Co., Ltd. | Suzhou Suncadia Biopharmaceuticals Co., Ltd. Jiangsu Hengrui Pharmaceuticals Co., Ltd. Shanghai Hengrui Pharmaceutical Co., Ltd. Henan Cancer Hospital | Phase 3 | Phase 3 | - | - | - | Breakthrough Therapy（China） Fast Track（United States） | - | Protease cleavable linker | Exatecan | - | SHR-A2102 | - | - | detail > | |
| Enfortumab Vedotin-ejfv | Enfortumab Vedotin-ejfv | Antibody drug conjugate (ADC) | Neoplasms Urogenital Diseases Digestive System Disorders Other Diseases | Tubulin inhibitors nectin-4 inhibitors | Astellas Pharma, Inc. | Seagen, Inc. Merck Sharp & Dohme Corp. Astellas Pharma, Inc. Astellas Pharma US, Inc. Astellas Pharma Global Development, Inc. Astellas Pharma China, Inc. Merck Sharp & Dohme LLC Astellas Pharma Europe Ltd. Astellas Pharma Europe BV Astellas Pharma Korea, Inc. Pfizer Inc. Astellas Pharma Australia Pty Ltd. Baxter Oncology GmbH | Approved | Approved | United States China European Union Japan United Kingdom Canada Australia Iceland South Korea Liechtenstein Norway | 2019-12-18 | 2024-08-13 | Accelerated Approval（United States） Breakthrough Therapy（United States） Orphan Drug（South Korea） Priority Review（United States） | - | Mc-Val-Cit-PABC-PNP | MMAE | 3 - 4 | Enfortumab Vedotin-ejfv | IgG1 - kappa | cysteinyl | detail > | |
| SKB410 | SKB410 | Antibody drug conjugate (ADC) | Neoplasms Skin and Musculoskeletal Diseases Urogenital Diseases | nectin-4 modulators | Sichuan Kelun Botai Biomedicine Co., Ltd. | MSD R&D (China) Co. Ltd. Merck Sharp & Dohme LLC Merck Sharp & Dohme Corp. Sichuan Kelun Pharmacy Institute Co., Ltd. Sichuan Kelun Botai Biomedicine Co., Ltd. | Phase 1/2 | Phase 1/2 | - | - | - | - | - | - | - | - | SKB410 | - | - | detail > | |
| VBC-103 | VBC-103 | Antibody drug conjugate (ADC) | Neoplasms Skin and Musculoskeletal Diseases | Trop-2 inhibitors nectin-4 inhibitors | Shanghai Chengfan Pharmaceutical Co. Ltd. | Shanghai Chengfan Pharmaceutical Co. Ltd. Avenzo Therapeutics, Inc. | Phase 1/2 | IND Application | - | - | - | - | - | - | - | - | VBC-103 | - | - | detail > | |
| BT-7480 | BT-7480 | Synthetic peptide | Neoplasms | 4-1BB agonists nectin-4 inhibitors Cytotoxic T lymphocytes stimulants | Bicycle Therapeutics Plc | Bicycle Therapeutics Plc | Phase 1/2 | - | - | - | - | - | - | - | - | - | BT-7480 | - | - | detail > | |
| SC-101 | SC-101 | Peptide drug conjugates | Neoplasms Skin and Musculoskeletal Diseases | nectin-4 modulators | Tianjin Conjustar Biotechnology Co., Ltd. | Tianjin Conjustar Biotechnology Co., Ltd. | Phase 2 | Phase 2 | - | - | - | Orphan Drug（United States） | - | - | - | - | SC-101 | - | - | detail > | |
| SYS-6002 | SYS-6002 | Antibody drug conjugate (ADC) | Neoplasms | Tubulin inhibitors nectin-4 inhibitors | CSPC Megalith Biopharmaceutial Co., Ltd. | Corbus Pharmaceuticals Holdings, Inc. CSPC Megalith Biopharmaceutial Co., Ltd. | Phase 2 | Phase 2 | - | - | - | Fast Track（United States） | - | Val-Cit | MMAE | 2 | SYS-6002 | - | - | detail > | |
| Bulumtatug fuvedotin | Bulumtatug fuvedotin | Antibody drug conjugate (ADC) | Neoplasms Urogenital Diseases Digestive System Disorders Other Diseases Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases | Tubulin inhibitors nectin-4 inhibitors | Jiangsu Maiweikang New Drug R & D Co Ltd | Mabwell (Shanghai) Bioscience Co., Ltd. Shanghai Junshi Biosciences Co., Ltd. Jiangsu Maiweikang New Drug R & D Co Ltd | Phase 3 | Phase 3 | - | - | - | Breakthrough Therapy（China） Fast Track（United States） Orphan Drug（United States） | - | IDM-Val-Cit-PABC | MMAE | 4 | Bulumtatug fuvedotin | IgG1 - kappa | cysteinyl | detail > | |
| Zelenectide pevedotin | Zelenectide pevedotin | Peptide drug conjugates | Neoplasms Endocrinology and Metabolic Disease Respiratory Diseases Skin and Musculoskeletal Diseases Urogenital Diseases | Tubulin inhibitors nectin-4 inhibitors | Bicycle Therapeutics Plc | Bicycle Therapeutics Plc BicycleTx Ltd. | Phase 2/3 | IND Approval | - | - | - | Fast Track（United States） | - | Val-Cit | MMAE | - | Zelenectide pevedotin | - | - | detail > | |
| SBT-6290 | SBT-6290 | Immune stimulating antibody conjugate (ISAC) | Neoplasms | TLR8 agonists nectin-4 inhibitors | Silverback Therapeutics, Inc. | Silverback Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | SBT-6290 | - | - | detail > |
Total 93 data
1
2
3
4
5
6
...
9
10
